TXMD TherapeuticsMD Inc.

+0.09  (2%)
Previous Close 5.90
Open 5.93
Price To book 8.68
Market Cap 1296716557
Shares 216,429,642
Volume 511,998
Short Ratio 19.27
Av. Daily Volume 3,492,539

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released December 5, 2016. NDA filing due December 2017.
Moderate to severe vasomotor symptoms (VMS)
CRL announced May 8, 2017. Company noted that FDA cited a lack of long-term endometrial safety data. Noted November 6 that NDA filing will be resubmitted in the coming weeks.
Moderate-to-severe vaginal pain

Latest News

  1. See what the IHS Markit Score report has to say about TherapeuticsMD Inc.
  2. TherapeuticsMD, Inc. breached its 50 day moving average in a Bearish Manner : TXMD-US : November 9, 2017
  3. Edited Transcript of TXMD earnings conference call or presentation 6-Nov-17 1:00pm GMT
  4. TherapeuticsMD to Present at Two Upcoming Investor Conferences
  5. Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and TherapeuticsMD
  6. Analyst William Tanner Angles for TherapeuticsMD to Secure a Late 2018 Approval in VVA
  7. TherapeuticsMD Inc (TXMD) Stock Fires Up to the Roof Following Positive FDA Resolution; William Tanner Cheers
  8. Why TherapeuticsMD Inc Is Skyrocketing Today
  9. TherapeuticsMD reports 3Q loss
  10. TherapeuticsMD Announces Third Quarter 2017 Financial Results
  11. TherapeuticsMD Announces Plan to Resubmit the New Drug Application for TX-004HR
  12. TherapeuticsMD, Inc. to Host Earnings Call
  13. TherapeuticsMD to Host TX-004HR Regulatory Update and Third Quarter Financial Results Conference Call and Webcast on November 6
  14. Is the Options Market Predicting a Spike in TherapeuticsMD (TXMD) Stock?
  15. ETFs with exposure to TherapeuticsMD, Inc. : November 2, 2017
  16. Research Report Identifies Campbell Soup, Hormel Foods, Southwest Airlines, TherapeuticsMD, Goodyear Tire, and General Mills with Renewed Outlook – Fundamental Analysis, Calculating Forward Movement
  17. TherapeuticsMD: Near Term Catalysts and Analysts Review
  18. ETFs with exposure to TherapeuticsMD, Inc. : October 20, 2017